BACKGROUND: Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, but evidence suggests a link between ICS usage and increased rates of respiratory infections. We assessed the composition of the asthmatic airways microbiome in asthma patients taking low and high dose ICS and the stability of the microbiome over a 2 week period. METHODS: We prospectively recruited 55 individuals with asthma. Of these, 22 were on low-dose ICS and 33 on high-dose ICS (16 on budesonide, 17 on fluticasone propionate). Sputum from each subject underwent DNA extraction, amplification and 16S rRNA gene sequencing of the bacterial component of the microbiome. 19 subjects returned for further sputum induction after 24 h and 2 weeks. RESULTS: A total of 5,615,037 sequencing reads revealed 167 bacterial taxa in the asthmatic airway samples, with the most abundant being Streptococcus spp. No significant differences in sputum bacterial load or overall community composition were seen between the low- and high-dose ICS groups. However, Streptococcus spp. showed significantly higher relative abundance in subjects taking low-dose ICS (p = 0.002). Haemophilus parainfluenzae was significantly more abundant in subjects on high-dose fluticasone propionate than those on high-dose budesonide (p = 0.047). There were no statistically significant changes in microbiota composition over a 2-week period. DISCUSSION: Whilst no significant differences were observed between the low- and high-dose ICS groups, increased abundance of the potential pathogen H. parainfluenzae was observed in patients taking high-dose fluticasone propionate compared to those taking high-dose budesonide. The microbiota were stable over fourteen days, providing novel evidence of the established community of bacteria in the asthmatic airways. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT02671773.
BACKGROUND: Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, but evidence suggests a link between ICS usage and increased rates of respiratory infections. We assessed the composition of the asthmatic airways microbiome in asthmapatients taking low and high dose ICS and the stability of the microbiome over a 2 week period. METHODS: We prospectively recruited 55 individuals with asthma. Of these, 22 were on low-dose ICS and 33 on high-dose ICS (16 on budesonide, 17 on fluticasone propionate). Sputum from each subject underwent DNA extraction, amplification and 16S rRNA gene sequencing of the bacterial component of the microbiome. 19 subjects returned for further sputum induction after 24 h and 2 weeks. RESULTS: A total of 5,615,037 sequencing reads revealed 167 bacterial taxa in the asthmatic airway samples, with the most abundant being Streptococcusspp. No significant differences in sputum bacterial load or overall community composition were seen between the low- and high-dose ICS groups. However, Streptococcusspp. showed significantly higher relative abundance in subjects taking low-dose ICS (p = 0.002). Haemophilus parainfluenzae was significantly more abundant in subjects on high-dose fluticasone propionate than those on high-dose budesonide (p = 0.047). There were no statistically significant changes in microbiota composition over a 2-week period. DISCUSSION: Whilst no significant differences were observed between the low- and high-dose ICS groups, increased abundance of the potential pathogen H. parainfluenzae was observed in patients taking high-dose fluticasone propionate compared to those taking high-dose budesonide. The microbiota were stable over fourteen days, providing novel evidence of the established community of bacteria in the asthmatic airways. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT02671773.
Authors: Steven L Taylor; Lex E X Leong; Fredrick M Mobegi; Jocelyn M Choo; Steve Wesselingh; Ian A Yang; John W Upham; Paul N Reynolds; Sandra Hodge; Alan L James; Christine Jenkins; Matthew J Peters; Melissa Baraket; Guy B Marks; Peter G Gibson; Geraint B Rogers; Jodie L Simpson Journal: Am J Respir Crit Care Med Date: 2019-08-01 Impact factor: 21.405
Authors: Yvonne J Huang; Snehal Nariya; Jeffrey M Harris; Susan V Lynch; David F Choy; Joseph R Arron; Homer Boushey Journal: J Allergy Clin Immunol Date: 2015-07-26 Impact factor: 10.793
Authors: Jodie L Simpson; Joshua Daly; Katherine J Baines; Ian A Yang; John W Upham; Paul N Reynolds; Sandra Hodge; Alan L James; Philip Hugenholtz; Dana Willner; Peter G Gibson Journal: Eur Respir J Date: 2015-12-02 Impact factor: 16.671
Authors: Geraint B Rogers; Nur Masirah M Zain; Kenneth D Bruce; Lucy D Burr; Alice C Chen; Damian W Rivett; Michael A McGuckin; David J Serisier Journal: Ann Am Thorac Soc Date: 2014-05
Authors: Pradeep Reddy Marri; Debra A Stern; Anne L Wright; Dean Billheimer; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2012-12-23 Impact factor: 10.793
Authors: Edith T Zemanick; J Kirk Harris; Brandie D Wagner; Charles E Robertson; Scott D Sagel; Mark J Stevens; Frank J Accurso; Theresa A Laguna Journal: PLoS One Date: 2013-04-30 Impact factor: 3.240
Authors: Nicole Acosta; Christina S Thornton; Michael G Surette; Ranjani Somayaji; Laura Rossi; Harvey R Rabin; Michael D Parkins Journal: BMC Microbiol Date: 2021-03-30 Impact factor: 3.605
Authors: Gail M Gauvreau; Beth E Davis; Guy Scadding; Louis-Philippe Boulet; Leif Bjermer; Adam Chaker; Donald W Cockcroft; Barbro Dahlén; Wyste Fokkens; Peter Hellings; Nikolaos Lazarinis; Paul M O'Byrne; Ellen Tufvesson; Santiago Quirce; Maurits Van Maaren; Frans H de Jongh; Zuzana Diamant Journal: Eur Respir J Date: 2022-08-25 Impact factor: 33.795